XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 22, 2020, the Company signed an agreement with Summit BioSciences, Inc. for services to be performed for product and method development, validation, GMP manufacturing and stability of an opioid antagonist nasal spray product. Total costs for this program are estimated to be up to approximately $6.5 million.